Logo

American Heart Association

  31
  0


Final ID:

Do Emerging HFpEF Treatments Work? The Role of Non-disease Modifying Treatments including SGLT2i, MRAs, GLP1s, and implantable hemodynamic monitors in Cardiac Amyloidosis.

  • Cuddy, Sarah  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Griffin, Jan  ( Medical University of South Carolina , Charleston , South Carolina , United States )
  • Author Disclosures:
    Sarah Cuddy: DO have relevant financial relationships ; Consultant:bridgebio:Active (exists now) ; Consultant:attralus:Active (exists now) ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Research Funding (PI or named investigator):aha:Active (exists now) ; Consultant:intellia:Past (completed) ; Research Funding (PI or named investigator):intellia:Active (exists now) ; Research Funding (PI or named investigator):alnylam:Active (exists now) ; Research Funding (PI or named investigator):alexion:Active (exists now) ; Research Funding (PI or named investigator):astrazenca:Active (exists now) ; Speaker:pfizer:Past (completed) ; Advisor:pfizer:Past (completed) ; Advisor:novo nordisk:Active (exists now) ; Advisor:astrazeneca:Active (exists now) ; Speaker:bridgebio:Past (completed) ; Speaker:novo nordisk:Past (completed) | Jan Griffin: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

More abstracts from these authors:
Discussant: nex-z, also known as NTLA-2001

Griffin Jan, Davis Margot, Cuddy Sarah

Novel Therapies in the Management of Cardiac Amyloidosis and Access to Care

Falk Rodney, Kittleson Michelle, Cuddy Sarah

You have to be authorized to contact abstract author. Please, Login
Not Available